
Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study
pharmafile | February 5, 2020 | News story | Research and Development | Bayer, Eylea, pharma
Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment of wet age-related macular degeneration (AMD) via two different Treat and Extend (T&E) dosing regimens.
The trial examined 246 participants, treating them with Eylea for three consecutive monthly doses before a bimonthly injection interval. After 16 weeks of treatment, the participants were randomised to either a two-week or four-week interval-adjusted T&E dosing regimen.
After 52 weeks, a change of 9.0 and 8.4 from baseline in best corrected visual acuity (BCVA) was recorded in the two-week group and the four-week group respectively, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS). These effects continued up to 96 weeks of treatment, alongside an average improvement of 7.6 letters and 6.1 letters in the two-week and four-week groups.
There are around 39,800 new cases of wet AMD each year in the UK, and symptoms of the disease can worsen into old age, potentially culminating in vision loss.
“Allowing greater flexibility of aflibercept injections in year one, and extension to intervals up to 16 weeks could provide significant benefits for patients and their carers, including fewer medical appointments, reduced waiting lists and an improvement in the overall burden associated with this treatment experience,” said Dr Jackie Napier, Medical Director of Ophthalmology at Bayer. “As well as ensuring that patients receive the level of care that suits the need of each individual, these results could contribute to relieving capacity pressures and treatment costs for overstretched NHS services”.
Matt Fellows
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






